hesperidin has been researched along with Atheroma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inada, K; Kanaoka, Y; Kataoka, Y; Koga, M; Omine, S; Yamauchi, A | 1 |
| Aihara, KI; Higashiguchi, F; Katagi, A; Kitagawa, T; Kurobe, H; Nakayama, T; Nishio, C; Sata, M; Shimabukuro, M; Sugasawa, N; Takumi, H | 1 |
2 other study(ies) available for hesperidin and Atheroma
| Article | Year |
|---|---|
Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages.
Topics: Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cardiovascular Diseases; CD36 Antigens; Down-Regulation; Hesperidin; Lipoproteins, LDL; Macrophages; Mice; Mice, Knockout; Plaque, Atherosclerotic; RAW 264.7 Cells; Scavenger Receptors, Class E; Varenicline | 2020 |
Inhibition of Atherosclerotic Plaque Development by Oral Administration of α-Glucosyl Hesperidin and Water-Dispersible Hesperetin in Apolipoprotein E Knockout Mice.
Topics: Administration, Oral; Animals; Antioxidants; Apolipoproteins E; Cholesterol; Diet, High-Fat; Glucosides; Hesperidin; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic | 2019 |